Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$227.60M
EBITDA Margin
-25.05%
TTM Avg
-32.88%
3Y Avg
-63.97%
5Y Avg
-61.52%
Market Cap
$225.24M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$231.37M
EBITDA Margin
-43.93%
TTM Avg
-56.69%
3Y Avg
-115.93%
5Y Avg
-139.79%
Market Cap
$231.77M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$232.72M
EBITDA Margin
-163095.33%
TTM Avg
-97357.05%
3Y Avg
-88166.59%
5Y Avg
-88166.59%
Market Cap
$220.93M
EBITDA Margin
-252.79%
TTM Avg
-276.80%
3Y Avg
-348.01%
5Y Avg
-340.44%
Market Cap
$235.08M
EBITDA Margin
37.26%
TTM Avg
38.63%
3Y Avg
43.69%
5Y Avg
46.28%
Market Cap
$235.66M
EBITDA Margin
10.49%
TTM Avg
1.20%
3Y Avg
-4.19%
5Y Avg
-40.04%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vogenx Inc. (VOGX) | $227.91M | N/A | N/A | N/A | N/A |
| Biodesix, Inc. (BDSX)vs › | $227.60M | -25.05% | -32.88% | -63.97% | -61.52% |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $225.24M | N/A | N/A | N/A | N/A |
| MacroGenics, Inc. (MGNX)vs › | $231.37M | -43.93% | -56.69% | -115.93% | -139.79% |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $231.77M | N/A | N/A | N/A | N/A |
| InflaRx N.V. (IFRX)vs › | $232.72M | -163095.33% | -97357.05% | -88166.59% | -88166.59% |
| Profound Medical Corp. (PROF)vs › | $220.93M | -252.79% | -276.80% | -348.01% | -340.44% |
| Utah Medical Products, Inc. (UTMD)vs › | $235.08M | 37.26% | 38.63% | 43.69% | 46.28% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $235.66M | 10.49% | 1.20% | -4.19% | -40.04% |
| SIGA Technologies, Inc. (SIGA)vs › | $235.97M | 25.65% | 38.25% | 43.91% | 51.79% |
Gross Margin
N/A
EBITDA Margin
N/A
Operating Margin
N/A
Net Margin
N/A
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
